Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
- Published In:
- The New England journal of medicine, 393(7), 648-659 (2025)
- Authors:
- Davies, Melanie J(13), Bajaj, Harpreet S, Broholm, Christa, Eliasen, Astrid, Garvey, W Timothy, le Roux, Carel W, Lingvay, Ildiko, Lyndgaard, Christian Bøge, Rosenstock, Julio, Pedersen, Sue D
- Database ID:
- RPEP-10633
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-10633APA
Davies, Melanie J; Bajaj, Harpreet S; Broholm, Christa; Eliasen, Astrid; Garvey, W Timothy; le Roux, Carel W; Lingvay, Ildiko; Lyndgaard, Christian Bøge; Rosenstock, Julio; Pedersen, Sue D. (2025). Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.. The New England journal of medicine, 393(7), 648-659. https://doi.org/10.1056/NEJMoa2502082
MLA
Davies, Melanie J, et al. "Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.." The New England journal of medicine, 2025. https://doi.org/10.1056/NEJMoa2502082
RethinkPeptides
RethinkPeptides Research Database. "Cagrilintide-Semaglutide in Adults with Overweight or Obesit..." RPEP-10633. Retrieved from https://rethinkpeptides.com/research/davies-2025-cagrilintidesemaglutide-in-adults-with
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.